Clinical Trial: TOLerogenic Potential of Hematopoietic Stem and Progenitor Cells and Inflammatory Bowel Disease

U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07740499) titled 'TOLerogenic Potential of Hematopoietic Stem and Progenitor Cells and Inflammatory Bowel Disease' on July 23.

Brief Summary: Pediatric refractory Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract, not responsive to current treatments. Since hematopoietic stem and progenitor cells (HSPCs) in the bone marrow display immunomodulatory functions and IL-10-producing regulatory cells regulate gut homeostasis, by combining state-of-the-art strategies for the ex-vivo manipulation and expansion of HSPCs and gene delivery systems to drive HLA-class II-restricted antigen presentation and expression...